Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says

MT Newswires Live08-28 00:21

Revolution Medicines (RVMD) receiving a broader-than-expected Food and Drug Administration label for Rasonque strengthens its commercial outlook, Oppenheimer said.

Management emphasized that the label does not set specific eligibility criteria, giving doctors and patients flexibility in treatment decisions, the analysts said in a note Wednesday, adding that this could allow Rasonque to be used in the first line before ongoing registrational studies are completed.

Management said the company is well prepared for the commercial launch, with supply, distribution, sales teams, patient services, and reimbursement support all operational from day one.

The company set a wholesale acquisition cost of $39,800 per 30-day supply. More than 2,000 patients have received Rasonque through preapproval access programs. Oppenheimer said it should support a smoother launch and greater physician familiarity with the drug.

"Rasonque's label flexibility, unprecedented survival benefit, compelling patient-reported outcomes, and launch readiness meaningfully increase the probability of commercial success," the analysts added.

Oppenheimer raised its price target on Revolution Medicines to $260 from $230, with an outperform rating.

Price: 220.36, Change: +4.92, Percent Change: +2.28

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2662008458?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-28 00:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662008458","market":"us","top_or_hot":-1,"title":"Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a> (RVMD) receiving a broader-than-expected Food and Drug Administration label for Rasonque strengthens its commercial outlook, Oppenheimer said.</p><p>Management emphasized that the label does not set specific eligibility criteria, giving doctors and patients flexibility in treatment decisions, the analysts said in a note Wednesday, adding that this could allow Rasonque to be used in the first line before ongoing registrational studies are completed.</p><p>Management said the company is well prepared for the commercial launch, with supply, distribution, sales teams, patient services, and reimbursement support all operational from day one.</p><p>The company set a wholesale acquisition cost of $39,800 per 30-day supply. More than 2,000 patients have received Rasonque through preapproval access programs. Oppenheimer said it should support a smoother launch and greater physician familiarity with the drug.</p><p>\"Rasonque's label flexibility, unprecedented survival benefit, compelling patient-reported outcomes, and launch readiness meaningfully increase the probability of commercial success,\" the analysts added.</p><p>Oppenheimer raised its price target on Revolution Medicines to $260 from $230, with an outperform rating.</p><p>Price: 220.36, Change: +4.92, Percent Change: +2.28</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-28 00:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RVMD\">Revolution Medicines</a> (RVMD) receiving a broader-than-expected Food and Drug Administration label for Rasonque strengthens its commercial outlook, Oppenheimer said.</p><p>Management emphasized that the label does not set specific eligibility criteria, giving doctors and patients flexibility in treatment decisions, the analysts said in a note Wednesday, adding that this could allow Rasonque to be used in the first line before ongoing registrational studies are completed.</p><p>Management said the company is well prepared for the commercial launch, with supply, distribution, sales teams, patient services, and reimbursement support all operational from day one.</p><p>The company set a wholesale acquisition cost of $39,800 per 30-day supply. More than 2,000 patients have received Rasonque through preapproval access programs. Oppenheimer said it should support a smoother launch and greater physician familiarity with the drug.</p><p>\"Rasonque's label flexibility, unprecedented survival benefit, compelling patient-reported outcomes, and launch readiness meaningfully increase the probability of commercial success,\" the analysts added.</p><p>Oppenheimer raised its price target on Revolution Medicines to $260 from $230, with an outperform rating.</p><p>Price: 220.36, Change: +4.92, Percent Change: +2.28</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IDNA","symbol_name":"iShares Genomics Immunology and Healthcare ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2662008458","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2662008458","pubTimestamp":1787847665,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Revolution Medicines (RVMD) receiving a broader-than-expected Food and Drug Administration label for Rasonque strengthens its commercial outlook, Oppenheimer said.Management emphasized that the label ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IDNA":"iShares Genomics Immunology and Healthcare ETF","CANC":"TEMA ONCOLOGY ETF","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BBH":"VanEck Biotech ETF","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4139":"生物科技","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","RVMD":"Revolution Medicines, Inc.","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","PTH":"Invesco Dorsey Wright Healthcare Momentum ETF"},"translate_title":"奥本海默表示，Revolution Medicines 的 Rasonque 标签扩大了商业机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1.5,"BBH":0.6,"IDNA":0.6,"CANC":0.6,"PTH":0.6},"content_text":"Revolution Medicines (RVMD) receiving a broader-than-expected Food and Drug Administration label for Rasonque strengthens its commercial outlook, Oppenheimer said.Management emphasized that the label does not set specific eligibility criteria, giving doctors and patients flexibility in treatment decisions, the analysts said in a note Wednesday, adding that this could allow Rasonque to be used in the first line before ongoing registrational studies are completed.Management said the company is well prepared for the commercial launch, with supply, distribution, sales teams, patient services, and reimbursement support all operational from day one.The company set a wholesale acquisition cost of $39,800 per 30-day supply. More than 2,000 patients have received Rasonque through preapproval access programs. Oppenheimer said it should support a smoother launch and greater physician familiarity with the drug.\"Rasonque's label flexibility, unprecedented survival benefit, compelling patient-reported outcomes, and launch readiness meaningfully increase the probability of commercial success,\" the analysts added.Oppenheimer raised its price target on Revolution Medicines to $260 from $230, with an outperform rating.Price: 220.36, Change: +4.92, Percent Change: +2.28","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2662008458","isCrawlerRequest":true}